IPO REVIEW | ON THE BOARD

11 MAY 2022

ASX - competing on a global scale

Kate Galpin, ASX 

More than 270 international companies are leveraging an ASX listing to support and fund their growth ambitions. The ASX’s Kate Galpin writes about how listing on ASX provides access to public-market investor capital at an earlier stage than on other major international exchanges. 

VIDEO INTERVIEW | ON THE BOARD

11 MAY 2022 

Getting to know Australian Clinical Labs (ASX:ACL)  

Interview with Melinda McGrath

Melinda McGrath, CEO of pathology provider, Australian Clinical Labs, spoke to On the Board about the company’s listing journey and how it has enabled them to get more operating leverage and gain market advantage. 

COMPANY PROFILE | ON THE BOARD 

11 MAY 2021

Microba Life Sciences trusts gut instinct with IPO 

Interview with Dr. Luke Reid, CEO 

We spoke to Dr Luke Reid about how an ASX listing has helped this biotech accelerate the commercialisation of it microbiome research in global markets.  

COMPANY PROFILE | ON THE BOARD 

11 MAY 2022 

BioTechNZ builds on New Zealand’s biotechnology strengths 

Interview with Dr. Zahra Champion, Executive Director

BioTech New Zealand is helping to build a vibrant ecosystem for biotech companies in NZ that better connects biotech researchers to companies across industry, and to global capital markets. 

IPO REVIEW | ON THE BOARD

27 JANUARY 2022

2021 ASX IPO Annual Review - a standout year

James Posnett, ASX 

2021 was a year of records in the ASX Listings business. The global Initial Public Offerings (IPO) market recorded highs in terms of capital raised and number of IPOs. Read more. 

ARTICLE | ON THE BOARD

27 JANUARY 2022

ASX in New Zealand 

Blair Harrison, ASX 

2021 in review: A pandemic, a taniwha, and three unicorns. Read more about the drivers and events that saw three major companies list on ASX.  

COMPANY PROFILE | ON THE BOARD 

10 NOVEMBER 2021

Fast growth allows Judo to list early 

Interview with Joseph Healey, CEO 

Judo has barely missed a beat since launch. The Melbourne-based company has become one of Australia’s leading fintech companies as it disrupts SME lending through an innovative hybrid model of technology and human bankers.  

INSIGHTS | ON THE BOARD 

27 JANUARY 2022 

Pandemic boosts growth in Australian fintech sector 

Simone Joyce, Chair of FinTech Australia 

The 2021 EY FinTech Australia Census noted a ‘perfect storm’ for financial technology innovation – a trend that could drive more fintech listings on ASX in the next few years. 

COMPANY PROFILE | ON THE BOARD 

27 JANUARY 2022 

ASX listing widens Harmoney Corp’s horizon

Interview with David Stevens, CEO

Harmoney Corp had two related goals when it listed on ASX in November 2020: access to capital and making a bigger push into the Australian personal-lending market. 

INSIGHTS | ON THE BOARD

23 FEBRUARY 2022 

NZ fintech sector's bright prospects  

Interview with Jason Roberts, FinTechNZ 

A growing ecosystem of fintech companies bodes well for future listings on ASX. We spoke to Jason Roberts about trends and opportunities in this sector. 

ARTICLE | TECH IPO

01 April 2022

Is it time to float? Why, when, and how to max a tech IPO

Joshua Tanchel, Deloitte

Deloitte spoke to ASX's Sasha Conoplia to get the latest on Australia’s tech sector and discover what it takes to make a successful IPO.

VIDEO | ON THE BOARD

10 NOVEMBER 2021

Getting to know Clarity Pharmaceuticals (ASX:CU6)

With Dr. Alan Bennett, Executive Chairman of Clarity Pharmaceuticals 

James Posnett speaks to Dr. Alan Bennett about his journey from investment banking to the largest biotech IPO to date on ASX  in August 2021.  

ARTICLE | ON THE BOARD

10 NOVEMBER 2021 

ASX-listed healthcare sector deepens and strengthens 

Kate Galpin, ASX 

There is growing momentum and interest in IPOs from the healthcare sector, read more about this trend. 

COMPANY PROFILE | ON THE BOARD 

10 NOVEMBER 2021

International highway opens for EROAD 

EROAD 

A dual listing on ASX is fueling growth and expansion for this NZ transport technology star. 

INSIGHT | ON THE BOARD 

10 NOVEMBER 2021 

The journey to IPO and beyond

PwC

The team from PwC shares their insights on the timelines and key steps that companies need to follow to set them up for a successful listing. 

VIDEO | ON THE BOARD

11 AUGUST 2021

Getting to know recently-listed company, Airtasker (ASX:ART)

With Tim Fung, CEO and Founder of Airtasker limited

ASX’s Giri Tenneti talks to Airtasker CEO Tim Fung about why the task-outsourcing platform decided to list on ASX.     

MARKET REVIEW | ON THE BOARD

11 AUGUST 2021 

Strong IPO performance in the first half of 2021 

Kate Galpin, ASX 

A strong first-half for IPOs in 2021 with 85 companies collectively raising A$3.5 billion. The IPO pipeline suggests a busy finish to the year. 

ARTICLE | ON THE BOARD 

11 AUGUST 2021

Accessing a larger capital pool through an ASX listing

Lysa McKenna, Link Group and Hugh Falcon, Macquarie Group

Two investment banking and share-registry experts share their thoughts on the merits of NZ companies dual or sole listing on ASX. 

INTERVIEW | ON THE BOARD 

11 AUGUST 2021 

New Zealand’s Aroa Biosurgery takes wound technology to the world

With Brian Ward, CEO of Aroa Biosurgery

Aroa Biosurgery listed at the height of the 2020 pandemic, and CEO, Brian Ward, spoke with On the Board about his company’s experiences since listing on ASX. 

The journey from pre-IPO to ASX listing 

Rajeev Gupta, Alium capital 

The reality is an ASX IPO suits all sorts and stages of a company’s evolution. The key is the motivation to undertake an IPO. Rajeev Gupta looks at the journey from pre-IPO to being an ASX public company. 

Get to know one of our recent ASX listings - Booktopia Group Limited

James Posnett, ASX 

Booktopia Group Limited (ASX: BKG) listed on the ASX on 4 December 2020, with a $316 million market capitalization on IPO. Tony Nash, CEO sits down with James Posnett, ASX, to share some of his observations and tips of going public on ASX. 

TAHITO indigenous ethical investing: bringing Māori wisdom to the financial markets

Temuera Hall, Tahito

TAHITO is a unique way of measuring companies using Māori ancestral knowledge combined with sophisticated ESG data capture technology and strong financial analysis. To date, the Fund has outperformed its benchmark.

Navigating ASX escrow (or lock-up) for beginners: the basics 

Belinda Chiu, ASX

Restrictions placed on a company’s shares on day one of trading can be a daunting thought for any founder or budding IPO prospect, but it doesn’t have to be an unnerving exercise once you wrap your head around a few key concepts. Belinda provides a beginner’s guide for companies navigating ASX escrow.

Technology IPOs adding high-growth companies to the ASX 

Max Cunningham, ASX 

ASX's EGM of Issuer Services and Investment Products explains how the outlook for the tech sector and tech listings has never looked brighter. 

ASX IPO Review 2020

James Posnett, ASX 

Looking back at ASX IPOs in 2020 and insights into trends and IPOs in the year ahead. 

Top 5 remuneration planning considerations for pre-IPO companies

Kirsten Ross CFA, Aon Advisory Australia

In this article, we start with framing the differences in approach to remuneration between the private and listed spaces and the top 5 remuneration planning considerations for pre-IPO companies.

ASX in New Zealand: 2020, the year the tyranny of distance became our “liberty of distance” 

Blair Harrison, ASX

It is of no surprise that technology company listings from New Zealand are trending upwards.

Resources and Tech lead charge for ASX IPOs 

Josh Collard, ASX

Secondary capital raisings have started to make way for IPOs as companies are dusting off deferred IPO plans to take advantage of current market conditions

Get to know ASX’s new public company: Aroa Biosurgery

Blair Harrison, ASX

Aroa Biosurgery (ASX: ARX) is ASX’s 57th New Zealand IPO and listed with a market capitalisation of $225 million

The Times They Are A Changin’: ASX Emerging as a Force for Tech and its Stakeholders

Richard Horton, Squire Patton Boggs

ASX as a truly robust fundraising and exit platform for mid-stage technology startups both locally and globally represents a remarkable achievement for the ASX in the world of tech

The changing face of capital markets 

James Lee, Jarden

Investors are facing a very simple problem; increased capital for a home in what is now a significantly more volatile and complex market.

ASX markets flare on secondary capital raisings 

Listings Business Development, ASX

As Australia has taken measures to stabilise its economy, COVID-19 has subdued global IPO activity, and ASX has been no exception. However, from March to May 2020, more than 200 listed companies have accessed ASX’s market to raise over $20 billion in secondary capital. This success has been underpinned by Australia’s highly active capital market, a robust but flexible regulatory regime, and the ability to mobilise capital quickly.

Get to know ASX's new public company - Atomo Diagnostics

Belinda Chiu, ASX

Atomo Diagnostics Limited (ASX: AT1) made its debut on the Australian Securities Exchange (ASX) on 16 April 2020, following an oversubscribed initial public offering (IPO) of $30 million at a price of $0.20 per share. John Kelly, co-founder and Managing Director discusses Atomo's unique IPO journey.

IPO preparation amidst market volatility

Gavan Carroll, Ord Minnett

Gavan Carroll, Executive Director, Corporate Finance at Ord Minnett, discusses how IPO markets are adjusting to erratic conditions and why companies can use this period to prime their business to be IPO-ready when the window re-opens.

The S&P/ASX All Technology Index and the Australian technology sector 

Cameron Gleeson, BetaShares

The S&P/ASX All Technology Index (XTX) was launched in February 2020 to provide a comprehensive benchmark of ASX-listed technology companies and to facilitate investment in the fast-growing sector. Cameron Gleeson, Senior Investment Specialist, BetaShares provides insights on the XTX, following the latest quarterly re-balance.